Table 2.
Simplified 2022 WHO diagnosis criteria for ETand post-ET MF; Adapted from: [6, 104].
|
| ET |
Post-ET MF |
|
|
| Major Criteria: |
Required Criteria: |
|
|
| Increased platelet count ≥ 450×109/L |
Previously diagnosed ET |
|
|
| Proliferation of enlarged, mature megakaryocytes with hyperlobulated nuclei. |
Grade 2 or 3 bone marrow fibrosis. |
|
|
| Criteria for BCR-ABL1, CML, PV, PMF, MDS or other myeloid neoplasms not met. |
Additional Criteria: |
|
|
| Presence of JAK2 (< 1% sensitivity assay). CALR or MPL (1-3% sensitivity assay) mutations. |
Anemia and decreased hemoglobin >2g/Dl from baseline.Leukoerythroblastosis. |
|
|
| Minor Criteria: |
New or increased palpable splenomegaly >5 cm from baseline |
|
|
| Presence of clonal marker (eg, ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2, SF3B1 mutations) or absence of evidence for reactive thrombocytosis |
Increased LDH levels above the reference range. |
|
|
| Requirements for diagnosis: |
Presence of at least 2 of the following: unexplained pyrexia (>37.5℃), weight loss (>10% in 6 months), night sweats. |
|
|
| All 4 major OR first 3 majors + minor criterion |
Requirement for diagnosis: |
|
|
| |
All required criteria + 2 or more additional criteria |
|
|
|
|
